Reneo is a clinical stage pharmaceutical company developing REN001 as a first-in-class treatment for patients with genetic mitochondrial diseases impacting muscle. The company aims to improve daily function and quality of life of these patients, specifically by improving how their mitochondria work and so preserving muscle function, and preventing muscle injury, weakness, and wasting. The company went public in April 2021, listing on Nasdaq with the ticker: RPHM.